Several big forces are behind this month’s surge, beginning with the clearing of some of the uncertainty that had dogged markets leading into the U.S. elections. Now, Democrat Joe Biden is firmly in place as the president-elect in Wall Street’s eyes, and investors have avoided their worst-case scenario of weeks or months of limbo with an unknown winner.
Investors also found encouragement in prospects that Washington will remain under divided political control. Republicans are on track to hold onto control of the Senate if they can win one of two upcoming runoff elections in Georgia. A split government would mean low tax rates and other pro-business policies could remain the status quo.
But the turbocharger for the market’s move higher has been a huge dose of hope as pharmaceutical companies come closer to delivering vaccines to a world beaten down by the COVID-19 pandemic. Several have reported encouraging data recently suggesting their vaccine candidates are highly effective.
Moderna said it would ask U.S. and European regulators Monday to allow emergency use of its COVID-19 vaccine. Its shares jumped 20.2% Monday.
Moderna follows Pfizer and German partner BioNTech in seeking to begin vaccinations in the U.S. in December. British regulators also are assessing the Pfizer shot and another from AstraZeneca.
That’s helped the stock market’s rally broaden out. Early in Wall Street’s recovery this spring, it was Big Tech that almost singlehandedly carried the market higher on expectations that work-from-home and other trends would mean bigger profits for them. But hopes for a more widespread economic recovery are now boosting stocks of companies whose profits are more closely tied to the economy’s strength.
Energy stocks in the S&P 500 ended November with a nearly 27% gain. It’s a sharp turnaround from earlier this year, when oil prices plunged as the pandemic kept airplanes, trucks and factories around the world idled or slowed.
Financial stocks have also been big winners on expectations that a stronger economy will create a stronger job market and higher interest rates. That could mean more people paying back loans made at more profitable rates for banks. The smaller stocks in the Russell 2000 index, meanwhile, closed out November with an 18.3% surge. The index fell 35.45 points, or 1.9%, to 1,819.82 Monday.
Many of those stocks, though, gave back some of their big gains Monday following discouraging economic reports and as investors locked in some profits from their big recent gains. Apache lost 7.4% and American Airlines fell 2.7%.
Many of the gains in November were justified by the good news from vaccine development, but markets will likely see more churning ahead, said Katie Nixon, chief investment officer at Northern Trust Wealth Management.
“You’ll see a diminishing impact from vaccine-related news and much more focus on when the economic recovery will take hold in a more organic way,” she said.
A report on Monday morning showed that growth in business activity in the Chicago area slowed more than economists expected. A separate report said that the pace of pending sales of homes was slower in October than expected. They’re the latest data to suggest the resurgent pandemic is dragging on the economy, including a pickup in layoffs.
With coronavirus counts and hospitalizations surging across the United States, Europe and elsewhere, governments are bringing back varying degrees of restrictions on businesses. An additional worry for markets is that the worsening pandemic will keep customers hunkered at home regardless of what kind of stay-at-home orders arrive. Experts are warning of a potentially brutal winter.
IHS Markit jumped 7.4% for Monday’s biggest gain in the S&P 500 after S&P Global said it would buy the data provider in a deal valued at $44 billion, including $4.8 billion of debt. S&P Global rose 3%.
European and Asian markets ended broadly lower. The yield on the 10-year Treasury ticked up to 0.84% from 0.83% late Friday.